Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedratinib in HU-resistant/intolerant PV or ET
NCT01420783Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2011
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of fedratinib in polycythemia vera (PV), essential thrombocythemia (ET), sponsored by Bristol Myers Squibb. Started Oct 2011; status: completed.
02
Drugs
fedratinib
03
Conditions
polycythemia vera (PV)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT01420783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01420783.